SUBSCRIBE
SUBSCRIBE
News   Deals

GlaxoSmithKline Buyback Hopes Rise After $1.7 Billion Quest Diagnostics Inc. Sale

February 2, 2011 | 
1 min read
LONDON, Feb 2 (Reuters) - Expectations that GlaxoSmithKline (GSK.L) will restart a share buyback programme in 2011 have risen with the sale of its stake in Quest Diagnostics (DGX.N) for some $1.7 billion, or $1.1 billion after tax.
Mergers & acquisitions Europe
GlaxoSmithKline
MORE ON THIS TOPIC
AbbVie's office in South San Francisco, California
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
A hand in a medical or laboratory glove holds a laboratory flask with coins with dollar sign. Investments in laboratory research and science. Concept of profit, making money, business. Modern design. Copy space.
Gene therapy
AstraZeneca Gains More Gene Therapy AAVs in JCR Deal Worth up to $825M
July 9, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Big fish with dollar sign eating many small ones. Competition, merger, business, monopoly concept. EPS 8 vector illustration, no transparency
M&A
Merck Makes Big Respiratory Play With $10B Acquisition of Verona
July 9, 2025
 · 
2 min read
 · 
Tristan Manalac
People standing on cracked ground. Concept vector illustration, sketch
Weight loss
Novo Nordisk’s Termination of Hims & Hers Deal Reignites Compounding Row
July 9, 2025
 · 
4 min read
 · 
Annalee Armstrong